Table 1.
Baseline Characteristics of Study Participants
| Characteristics | Number |
|---|---|
| Age(y), median(range) | 7.6 (1–18) |
| Age group, years | |
| ≥ 1, < 10 | 951 (57.0%) |
| ≥ 10 | 717 (43.0%) |
| Gender, n(%) | |
| Male | 993 (59.5%) |
| Female | 675 (40.5%) |
| Race, n(%) | |
| White | 1246 (74.7%) |
| Non-white | 422 (25.3%) |
| WBC(×109/L), median(range) | 33.7 (0.4–1306.0) |
| WBC group, ×109/L | |
| < 50 | 956 (57.3%) |
| ≥ 50 | 712 (42.7%) |
| Immunophenotype, n(%) | |
| B-Precursor | 721 (43.2%) |
| B Cell ALL | 497 (29.8%) |
| T Cell ALL | 242 (14.5%) |
| B precursor (Non-T, Non-B ALL) | 208 (12.5%) |
| DI, median(range) | 1.0 (0.51–1.9) |
| Karyotype, n(%) | |
| Normal | 739 (44.3%) |
| hypodiploidy | 98 (5.9%) |
| hyperdiploid | 395 (23.7%) |
| NA | 436 (26.1%) |
| Fusion gene, n(%) | |
| ETV6/RUNX1 | 213 (12.8%) |
| MLL | 56 (3.4%) |
| TCF3/PBX1 | 92 (5.5%) |
| BCR/ABL1 | 41 (2.5%) |
| Negative | 905 (54.3%) |
| Unknown | 361 (21.6%) |
| CNS status, n(%) | |
| CNS1 | 1353 (81.1%) |
| CNS2 | 245 (14.7%) |
| CNS3 | 70 (4.2%) |
| Prednisone response, n(%) | |
| Good | 1154 (69.2%) |
| Poor | 514 (30.8%) |
| BM blasts on Day+ 29, n(%) | |
| CR | 1625 (97.4%) |
| NR | 43 (2.6%) |
| BM relapse, n(%) | |
| No | 1359 (81.5%) |
| Yes | 309 (18.5%) |
| CNS relapse, n(%) | |
| No | 1555 (93.2%) |
| Yes | 113 (6.8%) |
| Testes site of relapse, n(%) | |
| No | 1657 (99.3%) |
| Yes | 11 (0.7%) |
| Chemotherapy protocol, n(%) | |
| 9906 | 222 (13.3%) |
| AALL0232 | 789 (47.3%) |
| AALL0331 | 415 (24.9%) |
| AALL0434 | 242 (14.5%) |
WBC white blood cell, DI DNA index, CNS central nervous system, BM bone marrow, NR not remission